900 related articles for article (PubMed ID: 32162812)
1. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
3. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
4. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
Front Oncol; 2022; 12():830816. PubMed ID: 35280779
[TBL] [Abstract][Full Text] [Related]
7. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
8. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
[TBL] [Abstract][Full Text] [Related]
10. Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
Cao W; Xu Y; Chang L; Gong Y; Li L; Mo X; Zhang X; Lin G; Zhou J; Liu D; Yi Y; Dai P; Zhu C; Liu T; Chu Y; Guan Y; Chen Y; Wang J; Xia X; Yang L; Yi X; Cheng Y
Mol Cancer Ther; 2019 Jun; 18(6):1158-1167. PubMed ID: 31015309
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
Barata PC; Koshkin VS; Funchain P; Sohal D; Pritchard A; Klek S; Adamowicz T; Gopalakrishnan D; Garcia J; Rini B; Grivas P
Ann Oncol; 2017 Oct; 28(10):2458-2463. PubMed ID: 28945843
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
13. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
15. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
16. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
[TBL] [Abstract][Full Text] [Related]
18. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
20. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA
Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
